XBiotech Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . XBiotech
XBIT Stock  USD 3.42  0.10  2.84%   
XBiotech financial statements provide useful quarterly and yearly information to potential XBiotech investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on XBiotech financial statements helps investors assess XBiotech's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting XBiotech's valuation are summarized below:
Gross Profit
3.4 M
Market Capitalization
107.3 M
Enterprise Value Revenue
24.051
Revenue
300 K
Earnings Share
(1.08)
There are currently one hundred twenty fundamental gauges for XBiotech that can be evaluated and compared over time across peers. All traders should confirm XBiotech's prevalent fundamentals against the performance from 2010 to 2025 and make sure the trends continue to evolve in the right direction. Market Cap is likely to drop to about 116.7 M in 2025. Enterprise Value is likely to gain to about (55.1 M) in 2025

XBiotech Total Revenue

327,750

Check XBiotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among XBiotech's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.9 M, Interest Expense of 985.4 K or Selling General Administrative of 7.9 M, as well as many indicators such as Price To Sales Ratio of 14.88, Dividend Yield of 0.18 or PTB Ratio of 0.63. XBiotech financial statements analysis is a perfect complement when working with XBiotech Valuation or Volatility modules.
  
Check out the analysis of XBiotech Correlation against competitors.
For more information on how to buy XBiotech Stock please use our How to Invest in XBiotech guide.

XBiotech Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets209.4 M260.6 M173.2 M
Slightly volatile
Short and Long Term Debt Total800900981
Slightly volatile
Other Current Liabilities6.5 M4 M5.2 M
Pretty Stable
Total Current Liabilities9.4 M7 M7.6 M
Pretty Stable
Total Stockholder Equity199.2 M251.7 M164.9 M
Slightly volatile
Property Plant And Equipment Net22.6 M28.6 M19.2 M
Slightly volatile
Accounts Payable2.5 M2.9 M2.1 M
Slightly volatile
Cash163.9 M230 M136.9 M
Slightly volatile
Non Current Assets Total29.6 M28.6 M24.3 M
Slightly volatile
Cash And Short Term Investments169.4 M230 M141 M
Slightly volatile
Common Stock Total Equity244.1 M307.4 M212.3 M
Slightly volatile
Common Stock Shares Outstanding36.4 M35 M33.2 M
Pretty Stable
Liabilities And Stockholders Equity209.4 M260.6 M173.2 M
Slightly volatile
Non Current Liabilities Total2 M1.9 M746.2 K
Slightly volatile
Other Current Assets830.3 K874 K6.2 M
Pretty Stable
Total Liabilities10.2 M8.9 M8.3 M
Pretty Stable
Property Plant And Equipment Gross25.8 M49.6 M22.8 M
Slightly volatile
Total Current Assets179.8 M232 M148.8 M
Slightly volatile
Common Stock248.6 M311.8 M213.1 M
Slightly volatile
Property Plant Equipment20.6 M30.2 M17.2 M
Slightly volatile
Net Tangible Assets236.7 M276.5 M182.9 M
Slightly volatile
Other Liabilities2 M1.9 M736.7 K
Slightly volatile
Net Invested Capital304 M251.7 M182 M
Slightly volatile
Net Working Capital263.6 M225 M148.7 M
Slightly volatile
Capital Stock220.6 M244 M272.1 M
Slightly volatile
Current Deferred Revenue3.6 M4 M4.4 M
Slightly volatile
Non Current Liabilities Other1.4 M1.7 M1.2 M
Slightly volatile

XBiotech Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization1.9 M2 M1.6 M
Slightly volatile
Selling General Administrative7.9 M5.4 M6.5 M
Slightly volatile
Other Operating Expenses37.1 M43.1 M32.2 M
Slightly volatile
Research Development25.5 M37.8 M23 M
Slightly volatile
Total Operating Expenses33.4 M43.1 M29.4 M
Slightly volatile
Interest Income12.4 M11.8 M2.7 M
Slightly volatile
Net Interest Income12.4 M11.8 M2.7 M
Slightly volatile
Reconciled Depreciation2.4 M2 M1.9 M
Slightly volatile
Selling And Marketing Expenses1.4 M1.6 M1.7 M
Slightly volatile

XBiotech Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation4.8 M3.8 M4.2 M
Pretty Stable
Begin Period Cash Flow146.4 M180.9 M121.4 M
Slightly volatile
Depreciation1.8 M2 M1.6 M
Slightly volatile
Capital Expenditures309.5 K325.8 K2.4 M
Pretty Stable
End Period Cash Flow163.9 M230 M136.9 M
Slightly volatile
Net Borrowings328 K369 K402.3 K
Slightly volatile
Change To Netincome5.9 M9 M6.2 M
Very volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio14.8823.9814.4332
Slightly volatile
Dividend Yield0.180.20.22
Slightly volatile
PTB Ratio0.630.660125.3769
Slightly volatile
Days Sales Outstanding99.2914569.8701
Slightly volatile
Book Value Per Share4.385.98374.7556
Slightly volatile
Stock Based Compensation To Revenue1.191.140.5152
Slightly volatile
Capex To Depreciation0.710.74732.7933
Pretty Stable
PB Ratio0.630.660125.3769
Slightly volatile
Payables Turnover0.590.621.4569
Pretty Stable
Sales General And Administrative To Revenue1.491.420.6947
Slightly volatile
Research And Ddevelopement To Revenue7.437.082.1351
Slightly volatile
Capex To Revenue0.110.130.1035
Slightly volatile
Cash Per Share3.745.66884.0554
Slightly volatile
Interest Coverage42.147.3751.6416
Slightly volatile
Days Payables Outstanding9626061.4 K
Slightly volatile
Net Debt To EBITDA4.524.06584.9105
Slightly volatile
Current Ratio20.4711.556922.5828
Slightly volatile
Tangible Book Value Per Share4.55.98374.8835
Slightly volatile
Receivables Turnover2.482.618.0849
Slightly volatile
Shareholders Equity Per Share4.385.98374.7556
Slightly volatile
Debt To Equity1.0E-41.0E-41.0E-4
Slightly volatile
Capex Per Share0.04070.04280.0792
Very volatile
Graham Net Net3.535.13373.8161
Slightly volatile
Revenue Per Share0.140.151.0542
Slightly volatile
Debt To Assets1.0E-41.0E-41.0E-4
Slightly volatile
Graham Number69.2677.9284.95
Slightly volatile
Price Book Value Ratio0.630.660125.3769
Slightly volatile
Days Of Payables Outstanding9626061.4 K
Slightly volatile
Company Equity Multiplier1.181.09231.0841
Slightly volatile
Total Debt To Capitalization1.0E-41.0E-41.0E-4
Slightly volatile
Debt Equity Ratio1.0E-41.0E-41.0E-4
Slightly volatile
Quick Ratio20.7411.556922.8648
Slightly volatile
Net Income Per E B T0.730.99920.9115
Pretty Stable
Cash Ratio17.811.431819.6773
Slightly volatile
Days Of Sales Outstanding99.2914569.8701
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.181.04211.0769
Very volatile
Price To Book Ratio0.630.660125.3769
Slightly volatile
Fixed Asset Turnover0.170.181.1881
Slightly volatile
Debt Ratio1.0E-41.0E-41.0E-4
Slightly volatile
Price Sales Ratio14.8823.9814.4332
Slightly volatile
Asset Turnover0.01780.01870.094
Slightly volatile
Gross Profit Margin0.460.750.3707
Slightly volatile
Price Fair Value0.630.660125.3769
Slightly volatile

XBiotech Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap116.7 M122.9 M416.6 M
Slightly volatile

XBiotech Fundamental Market Drivers

Cash And Short Term Investments200 M

XBiotech Upcoming Events

3rd of January 2024
Upcoming Quarterly Report
View
30th of September 2023
Next Fiscal Quarter End
View

About XBiotech Financial Statements

XBiotech shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although XBiotech investors may analyze each financial statement separately, they are all interrelated. The changes in XBiotech's assets and liabilities, for example, are also reflected in the revenues and expenses on on XBiotech's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue4 M3.6 M
Total Revenue345 K327.8 K
Cost Of Revenue2 M1.9 M
Stock Based Compensation To Revenue 1.14  1.19 
Sales General And Administrative To Revenue 1.42  1.49 
Research And Ddevelopement To Revenue 7.08  7.43 
Capex To Revenue 0.13  0.11 
Revenue Per Share 0.15  0.14 
Ebit Per Revenue(9.89)(9.40)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for XBiotech Stock Analysis

When running XBiotech's price analysis, check to measure XBiotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XBiotech is operating at the current time. Most of XBiotech's value examination focuses on studying past and present price action to predict the probability of XBiotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XBiotech's price. Additionally, you may evaluate how the addition of XBiotech to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY